Latest & greatest articles for tamsulosin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on tamsulosin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on tamsulosin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for tamsulosin

1. Tamsulosin

Tamsulosin Top results for tamsulosin - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for tamsulosin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

2. Effect of Tamsulosin on Passage of Symptomatic Ureteral Stones: A Randomized Clinical Trial

Effect of Tamsulosin on Passage of Symptomatic Ureteral Stones: A Randomized Clinical Trial 29913020 2018 06 18 2168-6114 2018 Jun 18 JAMA internal medicine JAMA Intern Med Effect of Tamsulosin on Passage of Symptomatic Ureteral Stones: A Randomized Clinical Trial. 10.1001/jamainternmed.2018.2259 Urinary stone disease is a common presentation in the emergency department, and α-adrenergic receptor blockers, such as tamsulosin, are commonly used to facilitate stone passage. To determine (...) if tamsulosin promotes the passage of urinary stones within 28 days among emergency department patients. We conducted a double-blind, placebo-controlled clinical trial from 2008 to 2009 (first phase) and then from 2012 to 2016 (second phase). Participants were followed for 90 days. The first phase was conducted at a single US emergency department; the second phase was conducted at 6 US emergency departments. Adult patients were eligible to participate if they presented with a symptomatic urinary stone

EvidenceUpdates2018

3. Efficacy and Safety of Tamsulosin in Medical Expulsive Therapy for Distal Ureteral Stones with Renal Colic: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial

Efficacy and Safety of Tamsulosin in Medical Expulsive Therapy for Distal Ureteral Stones with Renal Colic: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial 29137830 2018 01 09 1873-7560 2017 Nov 12 European urology Eur. Urol. Efficacy and Safety of Tamsulosin in Medical Expulsive Therapy for Distal Ureteral Stones with Renal Colic: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. S0302-2838(17)30972-7 10.1016/j.eururo.2017.10.033 Recent large high-quality (...) trials have questioned the clinical effectiveness of medical expulsive therapy using tamsulosin for ureteral stones. To evaluate the efficacy and safety of tamsulosin for distal ureteral stones compared with placebo. We conducted a double-blind, placebo-controlled study of 3296 patients with distal ureteral stones, across 30 centers, to evaluate the efficacy and safety of tamsulosin. Participants were randomly assigned (1:1) into tamsulosin (0.4mg) or placebo groups for 4 wk. The primary end point

EvidenceUpdates2018

4. Tamsulosin for the Expulsion of Ureteral Stones

Tamsulosin for the Expulsion of Ureteral Stones Emergency Medicine > Journal Club > Archive > September 2016 Toggle navigation September 2016 Tamsulosin for the Expulsion of Ureteral Stones Vignette You are working in TCC one busy evening, kicking ass and saving lives. In the middle of the primary survey of a critically ill level one trauma, you are suddenly hit by a sharp, 10 out of 10 pain in your right side. Thinking that Doug Schueurer might have punched you, you turn around swiftly and see (...) wonder if there is any real efficacy. When you get home, you decide to do a literature search and see what the evidence shows. PICO Question Population: Adult patients with ureteral stones not requiring urgent surgical intervention Intervention: Tamsulosin Comparison: Usual treatment (oral hydration, pain control, etc.) Outcome: Time to stone passage, pain level, need for surgical intervention, quality of life, patient satisfaction Search Strategy The articles chosen for the 2008 journal club were

Washington University Emergency Medicine Journal Club2017

5. COMBODART (dutasteride + tamsulosin), 5-? reductase inhibitor + alpha-blocker

COMBODART (dutasteride + tamsulosin), 5-? reductase inhibitor + alpha-blocker Haute Autorité de Santé - COMBODART (dutastéride + tamsulosine), inhibiteur de la 5-α réductase + alpha-bloquant Contribuer à la régulation par la qualité et l'efficience Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les Médicaments COMBODART (dutastéride + tamsulosine), inhibiteur de la 5-α réductase + alpha-bloquant Substance active (DCI (...) ) dutastéride tamsulosine (chlorhydrate de) UROLOGIE - Mise au point Nature de la demande Réévaluation SMR Avis de la CT du 14 décembre 2016 Intérêt clinique faible de COMBODART en remplacement de la prise séparée de tamsulosine et de dutastéride, si cette association en prise séparée est bien tolérée durant au moins 6 mois de traitement. COMBODART a l’AMM dans le traitement des symptômes modérés à sévères de l'hypertrophie bénigne de la prostate (HBP) et pour la réduction du risque de rétention aiguë

Haute Autorite de sante2017

6. Effect of Tamsulosin on Stone Passage for Ureteral Stones: A Systematic Review and Meta-analysis

Effect of Tamsulosin on Stone Passage for Ureteral Stones: A Systematic Review and Meta-analysis 27616037 2016 09 12 2017 02 24 1097-6760 69 3 2017 Mar Annals of emergency medicine Ann Emerg Med Effect of Tamsulosin on Stone Passage for Ureteral Stones: A Systematic Review and Meta-analysis. 353-361.e3 S0196-0644(16)30364-X 10.1016/j.annemergmed.2016.06.044 Tamsulosin is recommended for patients receiving a diagnosis of a ureteral stone less than 10 mm who do not require immediate urologic (...) intervention. Because of conflicting results from recent meta-analyses and large randomized controlled trials, the efficacy of tamsulosin is unclear. We perform a systematic review and meta-analysis to investigate the effect of tamsulosin on stone passage in patients receiving a diagnosis of ureteral stone. MEDLINE, EMBASE, and CENTRAL databases were searched without language restriction through November 2015 for studies assessing the efficacy of tamsulosin and using a double-blind, randomized, controlled

EvidenceUpdates2016

7. Randomised controlled trial: Tamsulosin and nifedipine did not improve stone passage over placebo nor were they cost-effective in ureteric stone disease

Randomised controlled trial: Tamsulosin and nifedipine did not improve stone passage over placebo nor were they cost-effective in ureteric stone disease Tamsulosin and nifedipine did not improve stone passage over placebo nor were they cost-effective in ureteric stone disease | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Tamsulosin and nifedipine did not improve stone passage over placebo nor were they cost-effective in ureteric stone disease Article Text Therapeutics/Prevention Randomised controlled trial Tamsulosin and nifedipine did not improve stone

Evidence-Based Medicine (Requires free registration)2016

8. Distal Ureteric Stones and Tamsulosin: A Double-Blind, Placebo-Controlled, Randomized, Multicenter Trial

Distal Ureteric Stones and Tamsulosin: A Double-Blind, Placebo-Controlled, Randomized, Multicenter Trial 26194935 2015 12 28 2016 05 02 2017 02 15 1097-6760 67 1 2016 Jan Annals of emergency medicine Ann Emerg Med Distal Ureteric Stones and Tamsulosin: A Double-Blind, Placebo-Controlled, Randomized, Multicenter Trial. 86-95.e2 10.1016/j.annemergmed.2015.06.001 S0196-0644(15)00480-1 We assess the efficacy and safety of tamsulosin compared with placebo as medical expulsive therapy in patients (...) with distal ureteric stones less than or equal to 10 mm in diameter. This was a randomized, double-blind, placebo-controlled, multicenter trial of adult participants with calculus on computed tomography (CT). Patients were allocated to 0.4 mg of tamsulosin or placebo daily for 28 days. The primary outcomes were stone expulsion on CT at 28 days and time to stone expulsion. There were 403 patients randomized, 81.4% were men, and the median age was 46 years. The median stone size was 4.0 mm in the tamsulosin

EvidenceUpdates2015

9. Solifenacin and tamsulosin (Vesomni) - benign prostatic hyperplasia

Solifenacin and tamsulosin (Vesomni) - benign prostatic hyperplasia Published 10 March 2014 Product Update: solifenacin succinate plus tamsulosin hydrochloride 6mg / 0.4mg modified release tablet (Vesomni ® ) (No: 945/14) Astellas Pharma Ltd 07 February 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE (...) : following an abbreviated submission solifenacin succinate plus tamsulosin hydrochloride 6mg / 0.4mg modified release tablet (Vesomni ® ) is accepted for use within NHS Scotland. Indication under review: for the treatment of moderate to severe storage symptoms (urgency, increased micturition frequency) and voiding symptoms associated with benign prostatic hyperplasia in men who are not adequately responding to treatment with monotherapy. In patients for whom concomitant use of solifenacin succinate

Scottish Medicines Consortium2014

10. Tamsulosin

Tamsulosin USE OF TAMSULOSIN IN PREGNANCY 0344 892 0909 USE OF TAMSULOSIN IN PREGNANCY (Date of issue: March 2014 , Version: 1 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . Summary Tamsulosin is an alpha 1A selective adrenoceptor-blocking drug used in the treatment of benign prostatic hypertrophy. While the drug (...) is not licensed for use in women, it is used off license in the treatment of renal calculi, renal colic, glomerulonephritis and other disorders of the urinary tract. There are no published data concerning gestational exposure to tamsulosin on which to assess the risk of adverse pregnancy or fetal outcome following use in pregnancy. Due to the lack of pregnancy safety data, it is not currently possible to provide an evidence-based risk assessment for exposure during pregnancy. In such situations

UK Teratology Information Service2014

11. Combination Therapy with Solifenacin and Tamsulosin Oral Controlled Absorption System in a Single Tablet for Lower Urinary Tract Symptoms in Men: Efficacy and Safety Results from the Randomised Controlled NEPTUNE Trial

Combination Therapy with Solifenacin and Tamsulosin Oral Controlled Absorption System in a Single Tablet for Lower Urinary Tract Symptoms in Men: Efficacy and Safety Results from the Randomised Controlled NEPTUNE Trial 23932438 2013 11 11 2014 06 30 2015 11 19 1873-7560 64 6 2013 Dec European urology Eur. Urol. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from (...) the randomised controlled NEPTUNE trial. 1003-12 10.1016/j.eururo.2013.07.034 S0302-2838(13)00749-5 Storage symptoms are particularly bothersome in men with lower urinary tract symptoms (LUTS) but may not be adequately treated by α-blocker monotherapy. To assess the efficacy and safety of a fixed-dose combination (FDC) of solifenacin and an oral controlled absorption system (OCAS) formulation of tamsulosin compared with placebo and compared with tamsulosin OCAS (TOCAS) monotherapy in men with moderate

EvidenceUpdates2013

12. Efficacy and Safety of Solifenacin Plus Tamsulosin OCAS in Men with Voiding and Storage Lower Urinary Tract Symptoms: Results from a Phase 2, Dose-finding Study (SATURN)

Efficacy and Safety of Solifenacin Plus Tamsulosin OCAS in Men with Voiding and Storage Lower Urinary Tract Symptoms: Results from a Phase 2, Dose-finding Study (SATURN) 23537687 2013 08 06 2014 03 31 2015 11 19 1873-7560 64 3 2013 Sep European urology Eur. Urol. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). 398-407 10.1016/j.eururo.2013.03.031 S0302-2838(13)00255-8 (...) Storage symptoms are often undertreated in men with lower urinary tract symptoms (LUTS). To evaluate the combination of an antimuscarinic (solifenacin) with an α-blocker (tamsulosin) versus tamsulosin alone in the treatment of men with LUTS. A double-blind, 12-wk, phase 2 study in 937 men with LUTS (≥ 3 mo, total International Prostate Symptom Score [IPSS] ≥ 13, and maximum urinary flow rate 4.0-15.0 ml/s). Eight treatment groups: tamsulosin oral controlled absorption system (OCAS) 0.4 mg; solifenacin

EvidenceUpdates2013

13. Tamsulosin for ureteral stones: a systematic review and meta-analysis of a randomized controlled trial

Tamsulosin for ureteral stones: a systematic review and meta-analysis of a randomized controlled trial Tamsulosin for ureteral stones: a systematic review and meta-analysis of a randomized controlled trial Tamsulosin for ureteral stones: a systematic review and meta-analysis of a randomized controlled trial Lu Z, Dong Z, Ding H, Wang H, Ma B, Wang Z CRD summary The authors concluded that tamsulosin was safe and effective for the expulsion of ureteral stones of less than 10mm. Publication bias (...) , limited reporting of trial quality, significant statistical and clinical variations, and the potential overstatement of the findings due to double counting of participants (acknowledged by the authors), mean that these conclusions seem unlikely to be reliable. Authors' objectives To evaluate the effectiveness of tamsulosin for ureteral stones. Searching PubMed, EMBASE , The Cochrane Library, Science Citation Index, and CBM were searched up to December 2011, without language restriction; search terms

DARE.2013

14. Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial

Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart (...) and Tamsulosin trial Bjerklund Johansen TE, Baker TM, Black LK Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study examined the cost-effectiveness of fixed-dose combination therapy (tamsulosin plus dutasteride) for benign

NHS Economic Evaluation Database.2012

15. Randomized Controlled Trial of Tamsulosin for Prevention of Acute Voiding Difficulty After Rectal Cancer Surgery

Randomized Controlled Trial of Tamsulosin for Prevention of Acute Voiding Difficulty After Rectal Cancer Surgery 22806208 2012 10 11 2013 04 03 2012 10 11 1432-2323 36 11 2012 Nov World journal of surgery World J Surg Randomized controlled trial of tamsulosin for prevention of acute voiding difficulty after rectal cancer surgery. 2730-7 10.1007/s00268-012-1712-z We conducted a randomized clinical trial to investigate the efficacy of the selective α(1A)-adrenoceptor antagonist tamsulosin (...) in preventing acute voiding difficulty after rectal cancer surgery. A total of 94 rectal cancer patients with an International Prostate Symptom Score (IPSS) of ≤7 were randomly assigned (1:1) to the tamsulosin group (0.2 mg/day orally for 7 days) (n = 47) or the control group (n = 47). The primary endpoint was the reinsertion rate of the urinary catheter after its removal on postoperative day (POD) 3. The secondary endpoints included the maximum (Qmax) and average (Qavg) urinary flow rates on POD 3

EvidenceUpdates2012

16. Tamsulosin for voiding dysfunction in women

Tamsulosin for voiding dysfunction in women Tamsulosin for voiding dysfunction in women Tamsulosin for voiding dysfunction in women Meyer LE, Brown JN CRD summary The review concluded that consistent positive findings across multiple clinical trials suggested that in women with lower urinary tract symptoms (particularly those with voiding dysfunction) tamsulosin may be an effective and safe treatment option. The authors’ conclusions reflect the evidence presented but limitations in the evidence (...) base make the reliability of the conclusions uncertain. Authors' objectives To evaluate the effectiveness of tamsulosin for lower urinary tract symptoms in women. Searching MEDLINE and EMBASE databases were searched to May 2012 for articles in English. Search terms were reported. Reference lists of retrieved articles were searched manually. Study selection Clinical trials that evaluated tamsulosin for the treatment of lower urinary tract symptoms in women were eligible for inclusion. Trials

DARE.2012

17. Dutasteride/Tamsulosin (Duodart) in benign prostatichyperplasia. Why associate?

Dutasteride/Tamsulosin (Duodart) in benign prostatichyperplasia. Why associate? 2011. DAR No 9. Dutasteride/Tamsulosin (Duodart®) in hiperplasia benign prostatic hyperplasia - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : : : DAR No 9. Dutasteride/Tamsulosin (Duodart®) in hiperplasia benign prostatic hyperplasia DAR No 9. Dutasteride/Tamsulosin (Duodart®) in hiperplasia benign prostatic hyperplasia Content tools Share it Why associate (...) ? The combination dutasteride/tamsulosin is indicated in the management of moderate to severe symptoms of BPH and in the reduction of the risk of acute urinary retention and surgery in these patients. In the only published study, the combination did not clearly demonstrate the superiority of the combination when compared to dutasteride in monotherapy with regard to the reduction of acute urinary retention or the need for surgery. Adverse reactions were more frequent in the group under combined therapy compared

Drug and Therapeutics Bulletin of Navarre (Spain)2011

18. WITHDRAWN: Tamsulosin for benign prostatic hyperplasia.

WITHDRAWN: Tamsulosin for benign prostatic hyperplasia. BACKGROUND: Benign prostatic hyperplasia (BPH) is a nonmalignant enlargement of the prostate which can result in bothersome lower urinary tract symptoms. The treatment goal for men with BPH is to relieve these bothersome symptoms. OBJECTIVES: This systematic review assessed the effects of tamsulosin in the treatment of lower urinary tract symptoms (LUTS) compatible with BPH. SEARCH STRATEGY: Trials were searched in computerized general (...) and specialized databases (MEDLINE, EMBASE, Cochrane Library), by checking bibliographies, and by contacting manufacturers and researchers. SELECTION CRITERIA: Trials were eligible if they (1) randomized men with BPH to receive tamsulosin in comparison with placebo, other BPH medications or surgical interventions and (2) included clinical outcomes such as urologic symptom scales, symptoms, or urodynamic measurements, and (3) had a treatment duration of 30 days or longer. Eligibility was assessed by at least

Cochrane2011

20. Efficacy and safety of tamsulosin for the treatment of benign prostatic hyperplasia: a meta analysis

Efficacy and safety of tamsulosin for the treatment of benign prostatic hyperplasia: a meta analysis Efficacy and safety of tamsulosin for the treatment of benign prostatic hyperplasia: a meta analysis Efficacy and safety of tamsulosin for the treatment of benign prostatic hyperplasia: a meta analysis Ren RM, Kou M, Lan XX CRD summary This review concluded that in comparison with placebo, tamsulosin improved international prostate symptom scores and maximum flow rates for patients with benign (...) prostatic hyperplasia with no significant difference in adverse events. A risk of missing data, paucity of evidence and a lack of information regarding study quality suggest that the findings should be interpreted with caution. Authors' objectives To determine the safety and efficacy of tamsulosin compared with placebo for the treatment of benign prostatic hyperplasia (BPH). Searching PubMed, EBSCO, CBM and CNKI were searched up to 2008. Search terms were reported. Science Direct and four relevant journals were searched up to April

DARE.2010